8-K current report · filed Nov 3, 2026

Pfizer Inc (PFE) 8-K Current Report: November 3, 2026

Item 5.02Item EX-99.1PFE overview

Short answer

Pfizer Inc (PFE) filed an 8-K current report with the SEC on November 3, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item EX-99.1 (Exhibit EX-99.1). Cecile Guegan appointed Pfizer CFO and executive vice president, effective November 1, 2026.

Pfizer Inc 8-K event analysis

AI summary of each reported item and its exhibits

Item 5.02 · Departure/Election of Directors or Officers

  • Cecile Guegan appointed Pfizer CFO and executive vice president, effective November 1, 2026
  • Permanent appointment follows interim CFO role beginning August 16, 2026, providing leadership continuity
  • Guegan brings more than 25 years of pharmaceutical finance experience, including extensive Pfizer operating exposure
  • Annual base salary set at $1,300,000
  • Target annual cash incentive set at $1,300,000, equal to 100% of base salary

Item EX-99.1 · Exhibit EX-99.1

  • Cecile Guegan appointed CFO and Executive Vice President effective November 1, 2026
  • Permanent appointment follows interim CFO tenure beginning August 16, 2026, reducing leadership uncertainty
  • Over 25 years of pharmaceutical finance experience, including acquisitions, integrations and portfolio forecasting
  • Mandate includes disciplined capital allocation and targeted investments intended to support revenue growth later in the decade

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Pfizer Inc 8-K filings

Get the next PFE 8-K as it lands

Follow PFE for push alerts, or ask the research agent what this filing means.